Xu Q - Search Results

1

Molecular engineering of AIE-active boron clustoluminogens for enhanced boron neutron capture therapy.

Ma W, Wang Y, Xue Y, Wang M, Lu C, Guo W, Liu YH, Shu D, Shao G, Xu Q, Tu D, Yan H. Ma W, et al. Among authors: xu q. Chem Sci. 2024 Feb 1;15(11):4019-4030. doi: 10.1039/d3sc06222h. eCollection 2024 Mar 13. Chem Sci. 2024. PMID: 38487248 Free PMC article.

2

miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells.

Jia Z, Zhang Y, Xu Q, Guo W, Guo A. Jia Z, et al. Among authors: xu q. Oncol Lett. 2018 May;15(5):7369-7375. doi: 10.3892/ol.2018.8207. Epub 2018 Mar 8. Oncol Lett. 2018. PMID: 29725450 Free PMC article.

3

⁶⁸Ga-PSMA PET/CT-Based Model Predicts Perineural Invasion of Prostate Cancer with Whole-Mount Sections.

Gao J, Fu Y, He K, Xu Q, Wang F, Guo H. Gao J, et al. Among authors: xu q. Mol Imaging Biol. 2024 Dec 16. doi: 10.1007/s11307-024-01974-2. Online ahead of print. Mol Imaging Biol. 2024. PMID: 39681774

4

VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.

Zhangyuan G, Wang F, Zhang H, Jiang R, Tao X, Yu D, Jin K, Yu W, Liu Y, Yin Y, Shen J, Xu Q, Zhang W, Sun B. Zhangyuan G, et al. Among authors: xu q. Oncogene. 2020 Feb;39(6):1213-1230. doi: 10.1038/s41388-019-1052-7. Epub 2019 Oct 11. Oncogene. 2020. PMID: 31605014

5

⁶⁸Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR-β Expression in Renal Cell Carcinoma Patients.

Gao J, Meng L, Xu Q, Zhao X, Deng Y, Fu Y, Guo S, He K, Shi J, Wang F, Zhang S, Guo H. Gao J, et al. Among authors: xu q. Mol Imaging Biol. 2022 Oct;24(5):759-768. doi: 10.1007/s11307-022-01725-1. Epub 2022 Apr 22. Mol Imaging Biol. 2022. PMID: 35451707

6

Correction: VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.

Zhangyuan G, Wang F, Zhang H, Jiang R, Tao X, Yu D, Jin K, Yu W, Liu Y, Yin Y, Shen J, Xu Q, Zhang W, Sun B. Zhangyuan G, et al. Among authors: xu q. Oncogene. 2020 Feb;39(6):1388. doi: 10.1038/s41388-019-1095-9. Oncogene. 2020. PMID: 31700153

7

[⁶⁸Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2α expression and therapeutic response to HIF-2α antagonists in patients with RCC.

Meng L, Zhang S, Gao J, Xu Q, Fu Y, Zhou YH, Wang F, Guo H. Meng L, et al. Among authors: xu q. Eur Radiol. 2022 Sep;32(9):6545-6553. doi: 10.1007/s00330-022-08738-y. Epub 2022 Mar 31. Eur Radiol. 2022. PMID: 35357538

8

Comprehensive evaluation of ⁶⁸Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma.

Gao J, Xu Q, Fu Y, He K, Zhang C, Zhang Q, Shi J, Zhao X, Wang F, Guo H. Gao J, et al. Among authors: xu q. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):561-569. doi: 10.1007/s00259-020-04916-6. Epub 2020 Jul 4. Eur J Nucl Med Mol Imaging. 2021. PMID: 32623502

9

Clinical and Pathological Characteristics of Hypertensive and Normotensive Adrenal Pheochromocytomas.

Lu Y, Li P, Gan W, Zhao X, Shen S, Feng W, Xu Q, Bi Y, Guo H, Zhu D. Lu Y, et al. Among authors: xu q. Exp Clin Endocrinol Diabetes. 2016 Jun;124(6):372-9. doi: 10.1055/s-0042-100911. Epub 2016 May 24. Exp Clin Endocrinol Diabetes. 2016. PMID: 27219882

10

Role of [^99mTc]Tc-Galacto-RGD₂ SPECT/CT in identifying metastatic differentiated thyroid carcinoma after thyroidectomy and radioactive iodine therapy.

Xu Q, Liu R, Wang J, Huang Y, Li S, Zhang L, Wang F. Xu Q, et al. Nucl Med Biol. 2020 Sep-Oct;88-89:34-43. doi: 10.1016/j.nucmedbio.2020.06.006. Epub 2020 Jun 20. Nucl Med Biol. 2020. PMID: 32688289

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20,443 results

Search Page

Filters